baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

LONZA N/ CH0013841017 /

2024-09-25 5:31:49 PM	Chg. -0.60	Volume	Bid7:52:20 PM	Ask7:52:20 PM	Market Capitalization	Dividend Y.	P/E Ratio
533.40CHF	-0.11%	95,447 Turnover: 50.92 mill.	530.60Bid Size: 100	530.00Ask Size: 10	39.72 bill.CHF	0.75%	60.07

GlobeNewswire 08-26 Simtra BioPharma Solutions Appoints Dr. Lidia Serina as Head of Development Sciences

GlobeNewswire 08-23 Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...

GlobeNewswire 08-08 Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08-06 Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 06-14 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...

GlobeNewswire 06-13 Repligen Announces CEO Transition Plan

GlobeNewswire 05-30 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...

GlobeNewswire 05-15 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...

GlobeNewswire 05-08 Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-08 Maravai LifeSciences Reports First Quarter 2024 Financial Results

GlobeNewswire 04-04 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...

GlobeNewswire 04-04 Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...

GlobeNewswire 02-27 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire 02-15 Galapagos presents at EBMT-EHA annual meeting 2024

GlobeNewswire 01-04 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...

GlobeNewswire 2023-12-19 Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...

GlobeNewswire 2023-12-09 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...

GlobeNewswire 2023-12-07 Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...

GlobeNewswire 2023-12-07 Business Update

GlobeNewswire 2023-11-06 Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 2023-11-01 Dr. Hartmut Tintrup joins Cellbox Solutions GmbH as new CEO

GlobeNewswire 2023-10-19 Viralgen welcomes back Andy Holt as CCO

GlobeNewswire 2023-10-16 Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumoc...

GlobeNewswire 2023-10-02 Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

GlobeNewswire 2023-09-20 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023

LONZA N/ CH0013841017 /

If you wish to receive reply to your feedback, please provide your email address.